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Available online at www.sciencedirect.comThis article explores new ideas about how the ECM-integrin
axis controls normal and malignant breast biology. We discuss
the role of integrins in mammary stem cells, and how cell–
matrix interactions regulate ductal and alveolar development
and function. We also examine the contribution of integrins to
tissue disorganisation and metastasis, and how an altered
stromal and ECM tumour microenvironment affects the cancer
cell niche both within primary tumours and at distant sites.
Finally, we mention novel strategies for integrin-directed breast
cancer treatment.
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Introduction
Building and maintaining epithelial tissues is a complex
process. Even in a relatively simple organ such as mam-
mary gland, the formation of a network of ducts and
associated alveoli requires sophisticated interactions be-
tween epithelium and the surrounding microenvironment
(Figure 1a,b). Ductal and alveolar breast epithelia adhere
to the type of ECM known as basement membranes
(BM). Stromal cells bind directly to interstitial ECM.
Both local epithelial cell–ECM interactions and long-
range communication between epithelium and stroma
are essential for all aspects of normal mammary gland
development and function [1–3].
The main ECM receptors of mammary epithelium
are integrins, which link ECM with the cytoskeleton
and signalling pathways and thereby establish an
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www.sciencedirect.com ECM-integrin-signalling axis. Integrins function as
microenvironmental sensors that control cell phenotype
and fate decisions [4]. They are on-off switches and
rheostats, which modulate cellular responses to growth
factor (GF) signals and cytokines, and convert tension
forces generated within the microenvironment into intra-
cellular chemical signals [5,6].
The prominence of integrins predicts that they will have
defining roles in mammary gland biology and disease.
Genetic deletion experiments reveal that integrins con-
trol nearly every aspect of mammary gland function [1,3].
Pathological and genetic studies implicate integrins in
both early breast cancer and malignant disease [7,8,9].
The central role of stromal cells in mammary develop-
ment and cancer also predicts key roles for integrins in the
fibroblast, adipocyte and macrophage compartment of
breast. However, genetic analyses have yet to explore
integrin function in stromal cell types.
In this review, we focus on new ideas about how the
ECM-integrin axis controls normal and malignant breast
biology.
Integrins have a central role in the mammary
stem cell niche
Mammary ducts are pseudo-stratified epithelia consisting
of basal myoepithelial cells that contact ECM, and lumi-
nal epithelia that line the ductal lumens [1]. In vivo
lineage tracing studies suggest that myoepithelial and
luminal stem cells diverge at birth, and once formed they
do not transition between each other [10]. Integrins are
key receptors to maintain mammary stem cells within
their niches. Deletion of b1-integrins from luminal cells
prevents transplanted mammary epithelial fragments
from forming new glands [11]. Genetic removal of b1-
integrins specifically within basal myoepithelial cells
affects stem cell renewal. Myoepithelial cells normally
divide parallel to the plane of the BM, but in the absence
of b1-integrins mitotic cells within the basal layer align
their spindle poles randomly, leading to a perturbation of
cell lineages and epithelial homeostasis [12].
As microenvironmental sensors, integrins provide a
mechanistic link between the stem cell niche and stem/
progenitor cell fates. The b1 and b3-integrin subunits, as
well as the b1 partner a2-integrin, and the b1/b4 partner
a6-integrin, are used to isolate stem and progenitor cells,
though their individual roles in normal mammary stem cell
biology are not yet known [13,14]. In cancer, a6 and b3
integrins are expressed in tumour-initiating cells (TICs)
and promote their self-renewal [15,16,17]. For b3-integrinCurrent Opinion in Cell Biology 2013, 25:633–641
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(a) Mammary gland from 14.5-day-pregnant mouse stained in whole-
mount with Carmine-Alum, showing ducts and lobules embedded within
connective tissue stroma. (b) A section through a mammary gland from
14.5-day-pregnant mouse stained with H&E, showing the discrete
organisation of epithelial alveoli and ducts surrounded by the stromal
ECM. The whole epithelial structure is embedded within the connective
tissue stroma, largely containing adipocytes in the mouse. (c) A section
through an invasive mammary tumour developed in K5DNbcat mouse
(courtesy of Aure´lie Chiche). Note that the tissue architecture is
completely disrupted. Bars: (a) 0.5 mm, (b,c) 0.2 mm.at least, the mechanism is through cooperation with TGFb
[16]. However integrins may have an additional and
unique function in mammary stem cells. Placing mammary
epithelia in suspension induces virtually all of the cells to
undergo anoikis, because they require integrin signalling to
prevent Bax-mediated death [18,19]. In ‘mammosphere’
stem cell assays performed with cell suspensions, floating
stem cells uniquely survive and proliferate to form mam-
mospheres, which can regenerate epithelial ducts/alveoli if
implanted into mammary fat pads [20].Current Opinion in Cell Biology 2013, 25:633–641 The adhesion signalling components of the ECM-integ-
rin axis, which provide normal mammary stem cells with
the capacity of anchorage-independent growth, remain to
be defined. In the Polyoma-Middle T breast cancer
model, focal adhesion kinase (FAK) maintains TICs,
and genetic deletion of Fak impairs tumorigenicity
[21]. Integrins and GFs also co-stimulate signalling path-
ways to maintain stem cells. In TICs of triple-negative
breast cancer, neuropilin-2 collaborates with a6b1 integ-
rin to activate the Fak/Ras/Mek pathway and the expres-
sion of the Hedgehog effector Gli1. In turn, Gli1 induces
the expression of both the stem cell regulator BMI-1 and
neuropilin-2, thereby creating an autocrine loop to main-
tain the stem cell niche [22,23].
Understanding the mechanisms linking integrin-
mediated recognition of the stem cell niche with the
profile of transcription factors that determine the identity
of both normal breast stem cells and TICs is a pressing
area for the future.
Cell–matrix interactions and integrins are
essential for ductal morphogenesis
The ductal architecture of mammary gland is formed by
unique mini-organs called terminal endbuds, which
invade stroma and bifurcate to produce a branching net-
work of ducts [24]. Endbuds are surrounded by BM and
require b1-integrins to generate motility [25]. 3D models,
where duct-like structures form and elongate through
ECM (i.e. Matrigel) in response to stromal GFs such as
FGF2, are providing novel insights into the ductal
morphogenesis programme [26]. Cells within cultured
‘endbuds’ do not extend lamellipodia in the way that
migrating cells on 2D substrata do, rather the cells have
smooth edges and appear to shuffle together through the
ECM [27]. Although b1-integrins are required for cul-
tured ducts to form (Streuli lab, unpublished data), the
mechanisms of integrin-dependent migration remain to
be defined.
Little is known about the processes controlling branching
of mammary ducts. In prepubertal gland, collagen I fibers
are oriented towards the long axis of the mammary fat
pad, and upon puberty, the branching epithelium follows
pre-existing collagen tracks suggesting that the stroma
provides spatial cues to direct branch growth [28].
Salivary gland is related to breast, and although mammary
and salivary differentiation programmes are cell autonom-
ous, ductal patterning is controlled directly by the stroma
of the host tissue [29]. This further argues that cell–matrix
interactions with stromally derived ECM proteins influ-
ence branch patterns. Indeed, fibronectin assembly and
the fibronectin-induced regulator Btbd7, local accumu-
lation of tenascin, MT1-MMP, and NC1 domains of
collagen-IV, as well as integrin-mediated ROCK1-myosin
II, FAK and ERK signalling, all have important roles in
glandular branching morphogenesis [29,30,31,32,33].www.sciencedirect.com
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discoveries about the GFs and ECM proteins involved,
promise to offer far-reaching insights into how normal
epithelial morphogenesis occurs and how it is subverted
during malignancy [34,35].
Integrins control the differentiated function of
mammary alveoli and lumen formation
By contrast to the elongated nature of ducts, lactational
alveoli are roughly spherical. Clusters of alveoli gather in
terminal ductal lobular units (Figure 1a). Alveoli contain a
single layer of polarised luminal epithelial cells sur-
rounded by sparse myoepithelia — both cell types con-
tact the basally located BM. Alveoli produce milk and
secrete it apically into the luminal space, from where it is
squeezed into ducts by the contraction of myoepithelial
cells. Genetic analyses reveal that luminal polarity and
myoepithelial contraction both require b1-integrins
[36,37] (Figure 2a).
Interactions between laminin and integrins orient the
microtubule network into an apical-basal direction byFigure 2
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www.sciencedirect.com recruiting microtubule plus tips via ILK and EB1
[37]. This triggers endocytosis of apical membrane
components, leading to the formation of an apical surface
at the opposite side of the cell where the lumen forms. It
is not yet known how integrins organise microtubules, but
possibilities include an ILK-mediated link to IQ-GAP
and Dia1 [38] and/or interactions between laminin-bind-
ing integrins, the PH-domain protein LL5, and the
microtubule plus-tip binding protein, Clasp [39]. Micro-
tubules may also dynamically regulate adhesion via the
MT motor protein KIF14, which controls inside-out
integrin activation via Rapil and Rap1 [40].
Once made, milk is ejected from the alveolar lumens into
ducts in response to oxytocin-induced myoepithelial con-
traction. The contractile force generated within cells
needs an equal and opposite force from the surrounding
ECM, which is transmitted through integrins. In the
contraction-relaxation cycle, oxytocin induces contraction
via a Rho/Rock/myosin tension pathway, while a3b1-
integrin relaxes tension via Fak/Rac/Pak signalling to
inhibit MLCK [36] (Figure 2a).nucleus
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ndent forces identified by genetic analyses. b1-integrins are required for
to lumens, and for myoepithelial cells to complete the stretch-relax cycles
n a variety of microenvironmental signals, including those from GFs, cell–
 interactions can regulate transcription and cell phenotype directly by a
C nuclear membrane complex, and nuclear cytoskeleton.
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luminal cells. The BM provides essential instructive
signals for mammary differentiation via b1-integrins
and specific components of adhesion complexes [4].
These signals guide tissue-specific gene expression in
conjunction with temporal cues from the cytokine, pro-
lactin [41–45]. In a separate mechanism, the elasticity of
the local microenvironment and its effects on intracellular
tension determine the levels of prolactin receptor —
tension blocks transcription of the receptor [46]. Tis-
sue-specific gene expression is therefore controlled not
only by biochemical signals, that is, soluble factors and
ECM, but also by mechanical forces [47].
Thus, converging signals from the cellular microenviron-
ment, comprising hormones, ECM proteins and stromal
tension coordinate alveolar cell function (Figure 2b).
Hormones and ECM respectively provide temporal and
spatial cues to activate milk synthesis in the appropriate
luminal cells, while perhaps expansive forces antagonise
endocrine signalling to protect alveolar integrity during
abstinence of suckling.
There is an emerging awareness that multiple types of
signals, that is, ECM proteins, soluble factors, physical
forces and cell–cell interactions, control metazoan cell
function. Deconvoluting how their intracellular effectors
all interconnect to specify different fates will need both
refined ways for analysing single cells and systems biology
approaches.
Integrins are checkpoints for GF signalling in
normal breast and cancer
Integrins ‘integrate’ cells into their tissues by binding
cells to the ECM and simultaneously organising the
cytoskeleton (Figure 2c). To link to the cell interior,
integrins, which have short non-enzymatic cytoplasmic
tails, assemble large multi-protein machines at the plasma
membrane [48]. The combined ability to bind ECM
proteins and control cytoskeletal dynamics and signalling
allow integrins to sense the physical and chemical nature
of the microenvironment, and to adjust intracellular
responses appropriately.
For example, integrins are checkpoints for the normal
proliferation of mammary cells during development [11].
In culture models, b1-integrins control the outcome of
EGF signalling, by activating a Rac1 signalling pathway
that controls Erk nuclear import [49]. Integrins signal
directly to cell cycle via the adhesion complex protein
talin, which is necessary for Fak activation and p21
suppression, and thereby providing the conditions for
GFs to drive cell cycle [50].
The function of integrins as adhesion checkpoints for
hormone and growth factor signalling is crucial for main-
taining the normal architecture and integrity of mammaryCurrent Opinion in Cell Biology 2013, 25:633–641 tissue [5]. Correspondingly, perturbations of the integrin
axis contribute to the major pathology of breast, which is
cancer. Too high levels of b1-integrins, b5-integrins or
b6-integrins [51–54], or too much activity of integrin
signalling components, co-operate with oncogenes to
drive excessive GF signalling. For example, Fak, Src
and small GTPase activators Trio, Vav3 and P-Rex1
are frequently upregulated in breast cancer [55–58]. This
leads to increased epithelial proliferation, or reduced
apoptosis in response to damage. Other elevated adhesion
complex proteins, for example, kindlin-1, contribute to
advanced breast disease, including metastasis [59].
Integrin function can also alter in disease progression.
a6b4-integrin is normally involved with cell adhesion to
BM via hemidesmosomes and seems to be not essential
for normal development [9,60]. However, in advanced
breast carcinomas a6b4 relocates to the leading front of
invasive cells, where it cooperates with ErbB2 and ErbB3
to promote inappropriate signalling [9,61].
Thus, as with the other classic cell cycle and apoptosis
checkpoints that become deregulated in cancer, so do the
integrin checkpoints. Integrins maintain tissue architec-
ture and function in the normal breast, while disrupting
the integrin axis alters signalling and causes tissue dis-
organisation and malignancy.
Altered integrins cause tissue disorganisation
and metastasis in breast cancer
An early event to arise during breast cancer initiation is
tissue disorganisation (Figure 1c). The luminal cells that
form the majority of breast cancers undergo massive bursts
of proliferation each menstrual/oestrus cycle and during
pregnancy. Epithelial proliferation is spatially orchestrated
in normal breast, but what distinguishes this process from
cancer is that the latter is disorganised. Moreover, tumours
originate initially from single cells. This has been modelled
in 3D cultured breast acini by using limiting dilutions of
lentiviral infection [62]. Some breast oncogenes, for
example, ErbB2, cause normal surrounding cells to extrude
the rogue oncogene-expressing cell into the acinar lumen,
where it proliferates abnormally. Other oncogenes require
assistance from a second change, for example, oncogenic
Akt1 requires MT1-MMP activation or talin depletion to
cause rogue cell displacement. This argues that altered
cell–matrix interactions may contribute to the early stages
of cancer, by disrupting the normal spatial architecture of
breast ducts and lobules.
In early breast hyperplasias and in situ carcinoma, epi-
thelial cell masses remain encapsulated by myoepithelial
cells and BM, but the cells loose polarity and the discrete
bi-layered organisation. Microarray data has revealed that
the expression of a variety of genes encoding cell–matrix
proteins is altered during the progression of early breast
cancers, including atypical ductal hyperplasia andwww.sciencedirect.com
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contributes to tissue disorganisation, loss of polarity also
has a key role. Polarity genes are deregulated in early
disease, and some, such as Par3, are potent metastasis
suppressors [64,65]. Similarly, reduced levels of adhesion
complex proteins that normally integrate breast epithelia
within their tissue environment contribute to malignancy.
For example the collagen receptor, a2b1-integrin, is a
metastasis suppressor. Its levels are reduced in advanced
breast cancer, and deleting the a2-integrin gene promotes
metastases [66]. Integrin signalling proteins such as
nischarin and the Rho-GEFs Vav2/3 are further tumour
suppressors in breast [15,16,67,68].
The b3-integrins may contribute to tumour angiogenesis
and progression of some classes of breast cancer, andFigure 3
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cells, their role in normal breast are not known. [69,70].
A gap in our knowledge is how levels of integrin signalling
proteins change in breast cancer. Future work to dissect
the impact of adhesion mutations on breast cancer, and a
greater emphasis on the epigenetic control of cell–matrix
adhesion is urgent, as this may provide valuable new
strategies to tackle disease [71–74].
The stromal microenvironment is a key player
in breast cancer
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e primary breast tumour site. This leads to tissue disorganisation and loss
n integrin signalling promote increased proliferation, reduced apoptosis,
 the secondary site by remodelling the stromal niche. This can occur in a
in embryogenesis (tenascin), and indirect remodelling via stromal cell
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638 Cell adhesion and migrationpoorer prognosis for cancer (Fig. 3a) [76]. This contributes
to tumorigenesis via integrin mechanosensing receptors,
leading to enhanced Rho-mediated contractility and acti-
vation of integrin signalling. For example in stiff matrices,
Fak promotes Mdm-2-dependent p53 degradation thereby
preventing apoptosis [77]. These conditions also activate
the Ras/Erk and PI3K pathways, further enhancing survi-
val and proliferation [78].
ECM proteins that are abnormally expressed by infiltrat-
ing tumour or stromal cells promote invasion and metas-
tasis. The laminin receptor, a6b4-integrin, regulates
expression of SPARC (secreted protein acidic and rich
in cysteine), which is involved with matrix remodelling
[79]. SPARC is negatively controlled by miR-29a, and
a6b4-integrin down-regulates this microRNA thereby
enhancing SPARC expression and promoting invasion.
Tenascin-C, often up-regulated in breast cancer, induces
Fak/Src activation, partial EMT, enhanced migration,
and quick progression to lung relapse [80]. Moreover,
elevated Tenascin-C enhances expression of the stem
cell regulators, musashi homolog 1 and leucine-rich
repeat-containing G protein-coupled receptor 5, and pro-
motes the growth of pulmonary micrometastases, while
its knock-down diminishes lung metastases (Fig. 3b)
[81]. Finally, periostin is a stromal ECM protein that
is abnormally expressed in the tumour microenvironment
and in metastases [82]. To initiate lung metastases, breast
cancer cells induce the expression of periostin in lung
stroma [83]. The establishment of a distant niche by
stromal cells in response to paracrine tumour cell signal-
ling appears to be an important step in metastasis for-
mation.
These new findings about how the stroma contributes to
breast cancer through altered expression of ECM proteins
and assembly of ECM architecture, and how tumour cells
prime the metastatic niche, profoundly change the way
we think about cancer progression.
Integrin-targeted therapies for breast cancer
Taken together, integrins have a central role in regulating
all aspects of mammary gland function, and perturbed
integrin signalling is required for breast cancer to progress
(Figure 3). The ECM–integrin axis is therefore a prom-
ising target for combatting disease [84]. Although hor-
mone and GF antagonists are effective for some types of
cancer, the more intractable cancers, for example, triple-
negative malignant lesions, remain incurable. More
emphasis on intervening with cell–matrix interactions
will considerably augment current treatments, by target-
ing the TIC niche and metastases.
Some integrin-directed approaches are in pre-clinical
trials. For example, anti-integrin antibodies, in combi-
nation with radiotherapy, may be showing early signs of
success [85,86]. Moreover, many integrin antagonists areCurrent Opinion in Cell Biology 2013, 25:633–641 currently under clinical development [87]. Small mol-
ecules such as cilengitide (a cyclic anti-integrin RGD
mimetic) may reduce metastatic colonisation and inhibit-
ing bone resorption in established metastases [88,89].
Particularly exciting are the new combinatorial
approaches to target cancer stromal cells: combined
antagonists of monocyte a4b1 integrin and SDFa or
IL-1b inhibit tumour inflammation and growth [90],
and a recombinant protein jointly targeting integrins
and VEGF is an effective inhibitor of breast cancer
angiogenesis [91].
However, although some of these strategies target cancer
cells themselves, careful use of therapies will be needed
in the light of integrin’s ability to both promote cancer
and to act as tumour suppressors.
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